Onkogenoks is the brand of Genoks Genetic Diseases Evaluation Center focused on cancer genetics and precision oncology solutions. Through Next-Generation Sequencing (NGS) technology, it offers hereditary cancer panels, comprehensive genomic profiling, liquid biopsy and solid-tumor panels, analyzing both hereditary and somatic mutations in detail. In this way it provides a scientific foundation for determining cancer risk, planning personalized treatment options and preventing unnecessary therapies.
A holistic approach in cancer genetics. Onkogenoks is the Genoks Genetic Diseases Evaluation Center brand focused on oncology and cancer genetics. With NGS-based hereditary cancer panels, tumor mutation analyses, comprehensive genomic profiling and liquid biopsy tests, it examines the genetic basis of cancer in detail.
A process spanning from risk assessment to treatment planning. Tests such as BRCA, HRR/HRD, prostate and colon panels reveal both hereditary cancer predisposition and genetic changes in existing tumors. In this way, screening strategies for early diagnosis can be planned, and eligibility for targeted drugs and immunotherapy is supported by genomic data.
Personalized oncology that reduces unnecessary treatments. Onkogenoks tests determine the molecular signature of the tumor, indicating which treatments may provide greater benefit, and help avoid therapies with low response chance or that are unnecessary. Results are presented in reports that are understandable for both patient and physician.
Precision oncology through genetic diagnosis.
With hereditary and somatic cancer tests, Onkogenoks provides genomic guidance for the entire process — from risk assessment to treatment selection. In this way, it supports a personalized oncology approach that aligns with each patient's cancer genetic profile.
We evaluate genetic alterations associated with hereditary and somatic cancers through BRCA, HRR/HRD, comprehensive hereditary panels and deep genomic profiling tests. All processes are carried out in Genoks Türkiye laboratories in accordance with current quality standards.
Hereditary cancers are associated with mutations in tumor suppressor genes and DNA repair genes inherited from the mother and father. The possibility of hereditary cancer arises when the same cancer type is seen in more than one family member, different cancer types are frequently observed in different individuals, or cancer is diagnosed at an early age.
Onkogenoks's genoXhere panels consist of the BRCA, breast/ovarian, prostate, colon, prime and plus panels. With gene contents determined according to current scientific data, they offer comprehensive evaluation for hereditary cancers.
The test groups below cover a broad range — from hereditary cancer panels to comprehensive genomic profiling. The scope and intended use of each panel should be evaluated within the content framework defined in the related technical documents.
You can access details of our panels by clicking the related cards.
638 DNA genes + 22 RNA driver genes · SNV, indel, CNV, HRD, MSI, TMB, fusions
The GenoXonco-Plus panel, designed by oncology specialists according to clinical targets, is optimized to cover the most critical targets in solid tumors. Genomic alterations and complex signatures are presented together in a single report.
SNV, indel, CNV and LOH analysis for 638 genes.
Fusions and aberrant splicing events for 22 driver genes.
Genomic signatures such as HRD, MSI and TMB are within the panel scope.
FFPE tissue sample · Next-generation sequencing (NGS)-based hybrid capture library preparation.
15 HRR genes · Genomic Instability Score · CE-IVD and clinical validation
Onkogenoks evaluates homologous recombination deficiency through BRCA1/2 and 13 additional HRR-related genes. Together with the Genomic Instability Score (GIS), it clearly reports an HRD-positive or HRD-negative result and supports the planning of targeted therapy options such as PARP inhibitors.
74 genes · Whole CDSs, hotspot, translocation and aberrant splicing genes
GenoxLiquid analyzes plasma-derived ctDNA obtained from a blood sample in patients diagnosed with solid tumors. The panel screens SNVs, indels, CNVs, TERT promoter mutations, intron-level fusions, aberrant splicing events and complex genomic signatures such as HRR/MSI across a broad gene set related to targeted and hormonal therapies.
It investigates hereditary pathogenic variants in the BRCA1 and BRCA2 genes. It helps assess hereditary risk in BRCA-related cancers, primarily breast and ovarian cancer.
It includes analysis of 25 genes associated with hereditary breast-ovarian cancer syndrome. In addition to BRCA1/2, genes such as ATM, BRIP1, CDH1, CHEK2 and other related genes are within the panel scope.
It examines 12 genes associated with hereditary prostate cancer. BRCA1/2, ATM, CHEK2, DNA repair pathway genes and mismatch repair genes are within the panel scope.
It includes analysis of 22 genes associated with hereditary colorectal cancers, including Lynch syndrome and familial adenomatous polyposis; genes such as MLH1, MSH2, MSH6 and APC are part of the panel.
A comprehensive hereditary panel in which 170 genes associated with increased cancer risk are screened by next-generation sequencing. It enables the combined evaluation of genes related to different organs and syndromes.
In addition to solid tumors, it includes analysis of 360 genes associated with predisposition to hematologic cancers. Its very broad gene content enables a detailed evaluation of the hereditary oncology spectrum.
Hereditary pathogenic variants in the BRCA1 and BRCA2 genes are associated with increased risk in various cancer types such as prostate, pancreatic and melanoma, as well as breast and ovarian cancer. The genoXhere-BRCA test evaluates mutations in these two genes by next-generation sequencing and supports the planning of appropriate screening programs.
| Sample Type | EDTA blood or DNA |
| Number of Genes | 2 (BRCA1, BRCA2) |
| Platform / method | Illumina / MGI / NGS |
Hereditary breast-ovarian cancer syndrome is associated with increased risk of prostate, pancreatic and melanoma cancers, as well as breast and ovarian cancer. Within the genoXhere-breast/ovarian panel, 25 genes — primarily BRCA1 and BRCA2, along with ATM, BRIP1, CDH1 and CHEK2 — are analyzed by next-generation sequencing.
| Sample Type | EDTA blood or DNA |
| Number of Genes | 25 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-prostate panel examines 12 genes known to be associated with hereditary prostate cancer using next-generation sequencing.
| Sample Type | EDTA blood or DNA |
| Number of Genes | 12 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-colon panel examines a total of 22 genes by next-generation sequencing, primarily the MLH1, MSH2 and MSH6 genes that cause Lynch syndrome — the most common hereditary colorectal cancer syndrome — and the APC gene that causes familial adenomatous polyposis.
| Sample Type | EDTA blood or DNA |
| Number of Genes | 22 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-prime test, consisting of 170 genes known to be associated with hereditary cancer syndromes and increased cancer risk, examines mutations that increase cancer risk using next-generation sequencing.
| Sample Type | EDTA blood or DNA |
| Number of Genes | 170 |
| Platform / method | Illumina / MGI / NGS |
The genoXhere-plus panel examines 360 genes known to be associated with predisposition to hematologic cancers in addition to solid cancers.
| Sample Type | EDTA blood or DNA |
| Number of Genes | 360 |
| Platform / method | Illumina / MGI / NGS |
The BRCA, breast/ovarian and HRR/HRD panels jointly evaluate genes associated with hereditary breast and ovarian cancers. In gynecologic oncology practice, they support the planning of PARP inhibitor treatment options.
POLE, P53, MMR deficiency and MSI are the key markers used in the molecular classification of endometrial cancer. This classification helps tailor the frequency of follow-up and treatment options to the individual.
Founded in 2008 as an R&D laboratory, Genoks offers a wide range of genetic testing services, including WGS, WES, cancer genetics, carrier screening, newborn screening, single-gene disorders, metabolic and neurodegenerative diseases, ophthalmology genetics and pharmacogenetic tests.
With the comprehensive NGS data bank obtained from the tests performed and its international collaborations, it aims to be one of the region's leading genome centers.
For detailed information about Onkogenoks oncology tests, panel selection or genetic counseling, you can reach us through the channels below.
Onkogenoks is the brand of Genoks Genetic Diseases Evaluation Center focused on cancer genetics and precision oncology solutions.
